Maziar Mike Doustdar, CEO of Novo Nordisk, speaks in the Oval Office during an event about weight-loss drugs at the White House in Washington, DC on November 6, 2025.
Andrew Caballero-Reynolds | Afp | Getty Images
Novo Nordisk entered 2026 with the momentum of a historic year in more ways than one – but recent weeks have delivered more drama than most companies might expect over a decade.
Advertisement
The Danish drugmaker kicked off the year with the explosive launch of the first-ever GLP-1 pill for obesity. Its recent challenges have centered around protecting its market share in the blockbuster weight loss drug market, all while its stock price swings wildly.
“Enough has occurred in the past week to occupy a few volumes,” said Deutsche Bank analyst Emmanuel Papadakis on Tuesday, as he — like many of his Wall Street peers — lowered his price target on the stock following the gloomy outlook.
Advertisement
The rapid news flow has given investors whiplash. So far in February, U.S.-listed Novo shares have traded across a spread ranging from $43.24 to $64.16, shedding as much as 14% in a single day only to gain 10% back in a later session.
Novo Nordisk U.S.-listed shares over the last month.
The latest developments add to a thorny situation for Novo as it risks being edged out by Lilly and the growing number of people taking cheaper compounded versions of semaglutide, which are unapproved copycats of Novo’s Wegovy jab.
Advertisement
CEO Mike Doustdar, who took the reins in August after the former CEO was ousted over misjudging the U.S. market and challenges there, has a plan to steer the company through what’s been described as a “show me” year.
His agenda is extensive: cracking down on those compounded knock-offs, sustaining strong demand for its newly launched obesity pill, building prescription volumes in the U.S. and bringing new, next-generation obesity and diabetes treatments to market.
In an interview with CNBC on Wednesday, Doustdar acknowledged the challenges ahead but said 2026 “is also a year of growth in many ways.”
“We will have more patients this year than ever before, we will produce more than last year and years before that,” he said.
Advertisement
Doustdar said around 246,000 patients are currently on the company’s Wegovy pill, which launched at the beginning of January and is already outpacing the early rollouts of existing GLP-1 injections.
“This, of course, tells me that while the investors are feeling a bit of a headwind on the pricing side and the whole business as you’re alluding to, they are hopefully getting convinced that over a period of time that would wash out and that growth will come,” Doustdar said.
Telehealth firms like Hims have profited massively from selling so-called compounded versions of injectable semaglutide under a regulatory loophole that allows other companies to sell copycats of the drugs if the branded medicines are in short supply. While branded semaglutide injections are no longer in short supply after a notable demand spike, the companies have continued to mass market cheaper versions directly to consumers, raising legal questions.
“We understand why compounding, mass compounding, got started. It was on the back of a shortage. We really don’t understand why it continued,” Doustdar told CNBC on Wednesday, noting that Novo’s opposition has nothing to do with medically necessary compounding for individual cases.
Advertisement
Hims last week announced plans to sell a compounded version of Novo’s newly launched Wegovy pill for roughly $100 less than Novo sells the branded version for, though it quickly backed down after Novo said it would sue over patent infringement and the FDA announced a broader crackdown on compounding. The agency also said it had referred Hims to the Department of Justice over potential violations.
The Hers website arranged on a laptop in New York, US, on Wednesday, Feb. 12, 2025.
Gabby Jones | Bloomberg | Getty Images
Novo moved to sue Hims on Monday over compounded versions of both injectable and oral semaglutide, adding to more than 130 lawsuits the drugmaker has filed against pharmacies, wellness clinics and other firms unlawfully marketing those copycats.
Advertisement
“The news last Thursday about the pill… was seen as kind of the last straw for many people,” Rothschild & Co Redburn analystSimon Baker told CNBC.
From the point of view of U.S. regulators, removing cheaper drugs from the market at a time when the Trump administration has made lower drug prices for Americans a priority might not have been an easy sell, Baker said.
But, “when we got the move on the pill, there was a realization that this has just gone a little bit too far,” he added. “You can’t have people launching knock-off versions of pills five weeks after the brand gets launched.”
“That would destroy the industry.”
Advertisement
If Novo can get the compounding issue under control, the company can potentially win back some market share and turn things around for sales projections, said BMO Capital Markets analyst Evan Seigerman.
Doustdar called it “a very strong signal” that the government acknowledged the compounding fight with Hims and “articulated that very publicly. We welcome that.”
Of course, a government crackdown on compounding wouldn’t clear the way for Novo alone.
Lilly’s obesity drug Zepbound already enjoys significant market share, and the company is preparing to launch its own oral version.
Advertisement
The market share race
A combination image shows an injection pen of Zepbound, Eli Lilly’s weight loss drug, and boxes of Wegovy, made by Novo Nordisk.
Hollie Adams | Reuters
The battle for U.S. market share could amount to a must-win for Novo — the weight loss segment accounted for more than half of its sales in 2025.
Lilly is estimated to have around 60% of the branded GLP-1 market globally, while Novo has about 39%. Novo has also highlighted a gap in the “preference share” for Wegovy versus Lilly’s injections.
Advertisement
Lilly’s obesity drug Zepbound has shown more pronounced weight loss than Wegovy and has become the preferred medicine among patients and prescribers, despite launching years after Novo’s drugs.
In the U.S., Novo estimates that between 7 and 8 patients out of 10 go to Lilly.
Meanwhile, in the compounding market, the share of copycats for Novo’s drug far outweighs that of Lilly’s.
“It’s a curious question as to why in the branded market, Lilly has a much bigger share than Novo but in the compounded market, there’s a lot more of Novo’s molecule than there’s of Lilly’s,” Baker noted. “We don’t know the answer.”
Advertisement
Novo is banking on the Wegovy pill to help with its eroding market share and says it’s already reaching entirely new patients. Doustdar has said that 88% of people on the pill are taking the lowest starter dose of the drug, signaling that many patients have been waiting on oral options.
Lilly is expected to launch its rival weight loss pill, orforglipron, in the second quarter of 2026. Investors are closely watching how that will pan out, especially as Novo has lost its first-mover advantage before.
“They’re putting a lot of muscle behind the marketing of [Wegovy pill], including now a reinvigorated direct-to-consumer channel, which they were a little bit late to arrive at,” TD Cowen analyst Michael Nedelcovych told CNBC. “That seems to be paying dividends.”
Still life of the new Wegovy semaglutide tablets on a white background. Its a prescription medicine used with a reduced calorie diet and .and physical activity.
Advertisement
Michael Siluk | Universal Images Group | Getty Images
Doustdar touted the pill’s efficacy, which is on par with the Wegovy injection and superior to Lilly’s oral drug based on separate clinical trials. The Wegovy pill showed around 16.6% weight loss on average compared to roughly 12.4% on average with Lilly’s oral drug.
“If you use these two numbers, basically you have a 40% difference between the efficacy of these pills,” he said. “I think this is going to be a very main, main selling point of the pill.”
When Lilly eventually launches orforglipron, its primary marketing point will likely be aimed at convincing customers that the Wegovy pill is inconvenient because of certain food restrictions. That makes Novo’s head start extra important as it offers them a chance to lay the groundwork and convince people of the contrary.
Advertisement
Novo contends that those dietary requirements won’t hinder uptake. But Leerink Partners analyst David Risinger told CNBC last week that it could help Lilly’s pill eventually generate greater sales globally.
Still, while sales of both companies’ drugs may soar, prices are coming down across the board.
U.S. pricing headwinds
The GLP-1 market is facing broad price erosion following landmark “most favored nation” deals between companies and the Trump administration. It’s unclear how much of the price decline can be offset by volume increases.
“No matter how well we do initially to catch up with the price decrease … of course mathematically, [it] takes a bit of time,” Doustdar said, adding the company is “very hopeful” and “working day and night to accelerate those volume uptakes.”
Advertisement
Analysts largely believe Novo is being intentionally cautious with its sales projections, baking in the expected pricing pressures.
“There are a number of pushes and pulls in 2026, some have quite high visibility, some have lower visibility… I think Novo have added in the things of high visibility more than the things of low visibility,” said Baker.
Where there’s higher visibility is where pricing is coming down, generics in Canada and a few other markets, and restrictions on Medicaid for some of their drugs, Baker said: “They’ve got these negatives in quite fully.”
“Given the problems they had last year, they don’t want to overpromise and underdeliver,” he said.
Advertisement
Novo’s guidance likely doesn’t include any reduction in the volume of compounded drugs on the market, as the FDA’s announcement of its “decisive steps” to restrict GLP-1 compounding came after the guidance was released.
But the price sensitivity of consumers for weight loss drugs remains a big unknown, which makes greater volumes and more access points important.
Novo is anticipating Medicare coverage for weight loss treatments, expected to begin later this year, to open up a 15 million-patient opportunity, Doustdar told CNBC.
Around 67 million Americans are covered by Medicare, but “when you take a look at specifically our products and the target group, I think around 15 million people would be a good number to target,” Doustdar said. Though he said Medicare access to obesity treatments will open up gradually.
Advertisement
Next-generation treatments
Flags with the logo of Novo Nordisk flutter next to the company’s factory in Hillerod on Nov. 12, 2025.
Sergei Gapon | AFP | Getty Images
Novo is also pinning its hopes on other drugs in its pipeline to help it claw back market share. That includes a higher dose – 7.2 milligrams – of Wegovy, which is waiting for FDA approval and could make the drug a stronger competitor to Zepbound.
Doustdar said that higher dose helps patients lose around 21% of their weight, which is “very much on par” with the highest dose of Zepbound. Wegovy, under its approved doses, has shown around 15% weight loss on average in clinical trials.
Advertisement
“When that comes to the market, my thought, my wish, my hope is that people will realize, OK, now we have two products with similar efficacy,” Doustdar said.
He added that “hopefully will also change the dynamic as we go forward,” referring to the market’s increasing preference for Zepbound.
BMO’s Seigerman said it’s difficult to say whether that will be the case, as Zepbound is already entrenched as the best product in the injectable market.
Later this year, Novo expects its next-generation treatment called CagriSema to enter the market. That experimental weekly injection combines semaglutide with cagrilintide, which mimics another gut hormone called amylin.
Advertisement
Novo Nordisk has defended CagriSema’s trial results, which disappointed investors, coming in under the expected 25% weight loss on average.
On Wednesday, Doustdar said the company was “penalized quite harshly by the stock market” for those results, which showed around 23% weight loss. But he said the drug would be “one of the best products out there” if it were available today.
To assess the real efficacy of the drug, “you need to look at all the data together,” he added, pointing to three upcoming phase three trials for the drug, including one study that pits CagriSema against Zepbound.
When asked whether Novo needs to further diversify away from obesity like competitors, Doustdar argued that the company doesn’t see obesity or diabetes as a single, monolithic disease and sees more opportunity in developing multiple, specialized therapies within the category.
Advertisement
While the world labels millions of patients simply as “obese,” he said the underlying biology and severity of the condition vary widely – from someone who needs to lose a modest amount of weight to someone with severe complications like fatty liver disease requiring a transplant.
And as the market matures, Novo’s sales are still growing year-on-year on a constant currency basis, albeit at a slower pace than before. Only time will tell when, or if, that will change.
SlateStone Wealth Chief Market Strategist Kenny Polcari analyzes the upward trend in the markets amid developments in the conflict with Iran on ‘Varney & Co.’
Apple is scrapping its high-end Mac Pro desktop after two decades, signaling a shift in how the tech giant targets professional users, according to reports.
The company has quietly removed the Mac Pro from its website, according to Bloomberg and 9to5Mac, marking the end of a product line that once served as a “halo” device for video editors and developers. The machine, known for its modularity and “cheese grater” design, carried a starting price of $6,999.
Advertisement
The move underscores Apple’s pivot toward more scalable devices powered by its proprietary silicon. By streamlining its lineup, Apple is prioritizing higher-margin, integrated hardware like the Mac Studio – a compact desktop that offers comparable performance to the Mac Pro at a significantly lower entry cost.
A customer looks at a Mac Pro workstation at Apple’s flagship store on Nanjing Road in Shanghai, China, June 2, 2021. (Costfoto/Future Publishing via Getty Images)
The decision comes as Apple marks its 50th anniversary, highlighting its evolution from a niche enthusiast hardware maker into a global company built on mass-market, tightly integrated ecosystems.
Apple employees help customers at the Fifth Avenue Apple Store on new product launch day on Sept. 19, 2025 in New York City. (Michael M. Santiago/Getty Images)
Apple has been selling through remaining inventory in retail stores. The company confirmed to 9to5Mac that it has no plans for future updates to the Mac Pro line, effectively ending the era of the internally expandable Apple desktop.
Apple’s new Mac Pro sits on display in the showroom during Apple’s Worldwide Developer Conference (WWDC) in San Jose, California on June 3, 2019. (Brittany Hosea-Small /AFP via Getty Images)
The shift reflects Apple’s broader strategy to consolidate its desktop lineup around fewer, more scalable products aligned with its in-house chip roadmap.
Apple shares are up fractionally in afternoon trade and are down about 6.2% year to date.
FOX Business correspondent Jeff Flock joins ‘Varney & Co.’ to break down the surge in SUV and truck sales, the slowdown in electric vehicle demand and how billions in tariffs are reshaping the auto industry.
A shift in the auto market is becoming harder to ignore as consumer demand tilts back toward larger, gas-powered vehicles, even as electric vehicles struggle to maintain momentum.
FOX Business correspondent Jeff Flock joined FOX Business’ Stuart Varney on “Varney & Co.” to report from the New York Auto Show, where automakers are leaning into SUVs and trucks amid changing buyer preferences.
Nissan Americas Chairman Christian Meunier discusses the debut of the 2027 Z Nismo at the New York Auto Show, highlighting performance upgrades and the brand’s next-generation sports car vision on ‘Mornings with Maria.’
Recent sales data underscores that pivot. Midsize SUVs and trucks are seeing notable gains, while smaller cars and electric vehicles are losing ground, highlighting a widening gap between industry ambitions and what consumers are actually buying.
According to Cox Automotive and Kelley Blue Book, midsize SUV sales are up 15%, midsize truck sales are up 14%, while compact car sales are down 8% and EVs are down 26% in February compared to the same time last year. EV momentum has become increasingly uneven. Electric vehicles reached 10.5% of U.S. new-vehicle sales in the third quarter of 2025 but fell to 5.8% in the fourth quarter as incentives faded, highlighting a sharp pullback after earlier gains.
Nissan Americas Chairman Christian Meunier pointed to another pressure shaping the market: tariffs. Automakers and suppliers have absorbed billions of dollars in added costs, limiting their ability to pass those expenses on to buyers.
A vehicle frame moves down the assembly line at the Nissan Motor Co. manufacturing facility in Tennessee. (Luke Sharrett/Bloomberg / Getty Images)
“It’s a lot of money, but it’s a lot less than the exposure we had a year ago when it was implemented,” Meunier said.
Interior Secretary Doug Burgum commends President Donald Trump’s economic agenda on ‘The Evening Edit.’
“At the very beginning, we had an exposure of $4 billion. We took it down to $1.5 billion in 25, and we’re going to get it down to zero. That’s our mission to build as many cars in the U.S. as we can,” Meunier said.
IndiGo, India’s largest airline by fleet size, has named the head of the International Air Transport Association as its new chief executive, as it emerges from a turbulent period of flight disruptions that shaved billions off its market value.
Andrew Hecht is a 35-year Wall Street veteran covering commodities and precious metals.
He runs the investing group The Hecht Commodity Report, one of the most comprehensive commodities services available. It covers the market movements of 20 different commodities and provides bullish, bearish and neutral calls; directional trading recommendations, and actionable ideas for traders. Learn more.
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
The author always has positions in commodities markets in futures, options, ETF/ETN products, and commodity equities. These long and short positions tend to change on an intraday basis.
Advertisement
Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
Sea Harvest has accused Fisheries Minister Jackie Jarvis of giving in to political pressure over the demersal fish ban, during a trial held at the state’s highest court.
Environment Agency increases checks on water companies in a bid to improve performance in the water industry
15:11, 31 Mar 2026Updated 16:19, 31 Mar 2026
One of Northumbrian Water’s treatment works
Regulators uncovered almost 500 breaches of environmental rules by water companies in the North last year as they carried out a record number of inspections. The Environment Agency said it had expanded its inspections of treatment works, sewage pumping stations and storm overflows, completing more than 3,300 checks of water company assets belonging to United Utilities, Yorkshire Water and Northumbrian Water in the past year.
Inspection teams uncovered 495 permit condition breaches in the North, where companies are failing to comply with environmental legislation. More than 3,000 breaches were found nationally.
Advertisement
Helen Wakeham, director for water at the Environment Agency, said: “Inspections are a vital preventative measure, with our teams issuing over 3,000 individual actions to water companies, including repairing sewage works and upgrading infrastructure. Together, this will drive meaningful improvements in performance, hold persistent offenders to account and ultimately create a cleaner water environment.”
Water minister Emma Hardy added: “Thanks to our investment in the Environment Agency, inspectors are out in force, checking water company assets at unprecedented levels and taking action where standards aren’t met. This greater oversight of water companies coupled with our long-term reforms will prevent problems before they occur and ensure serial offenders are punished, ensuring a healthy, sustainable water system for the future.”
James Wallace, chief executive of campaign group River Action, said: “It is good to see the Government getting serious about water quality, but inspections alone will not fix the problem.
“With prosecutions taking years to reach court and fines far too low, water polluters are not being properly held to account. The upcoming Water Reform Bill is a once-in-a-generation opportunity to reset the system.”
Advertisement
Stephanie Pullan, director of asset management at Yorkshire Water, said: “We remain absolutely committed to achieving 100% compliance at all of our wastewater assets and welcome increased levels of oversight from our regulators. While many of the breaches identified were minor, we take all breaches seriously and act as quickly as possible to remediate any issue identified.
Yorkshire Water’s Naburn Sewage Treatment Works.(Image: Google Maps)
“We have clear plans in place to tackle compliance at our sites, which includes increasing our own inspections and the deployment of more technology to identify potential issues before they impact our operations or the environment.
A Northumbrian Water spokesperson said: “We welcome the Environment Agency’s inspections and work closely with them to make sure our wastewater sites continue to operate as they should.
“During these visits, no serious issues have been reported. Where actions are identified, they are usually minor, such as labelling or routine maintenance requirements, and low risk for pollution or environmental harm. We’re open with the Environment Agency and keep them updated as actions are completed.
Advertisement
“We’re committed to improving our performance and between 2025 and 2030 we are investing £1.7bn on environmental improvements. These are helping to reduce the number of spills from storm overflows and improve our coasts and rivers.”
A United Utilities spokesperson said: “We continue to work constructively and openly with the Environment Agency and our other regulators. We take proactive action whenever issues arise and continually strive to improve our operational performance. Our focus remains on delivering our environmental investment programme and meeting the high standards our customers and regulators rightly expect.”
British companies are investing less in their domestic economy than almost any of their G7 counterparts, reinforcing long-standing concerns about productivity and growth as rising energy costs add fresh pressure on industry.
Analysis from Institute for Public Policy Research (IPPR) shows that private sector investment in the UK amounted to just 11.1 per cent of GDP in 2023, the second-lowest level in the G7, ahead only of Canada at 10.8 per cent.
By comparison, Japan leads the group with investment equivalent to 18.2 per cent of GDP, followed by France at 12.6 per cent and Germany at 11.9 per cent, highlighting the scale of the UK’s relative underperformance.
The findings underline a persistent structural issue. The UK has consistently ranked near the bottom of the G7 for business investment since the global financial crisis, and has remained below the group average every year since 2001.
According to the IPPR, this chronic underinvestment has constrained productivity growth for years, limiting the ability of businesses to expand capacity, adopt new technologies and improve efficiency.
Advertisement
One of the clearest indicators of this gap is capital intensity, the amount of equipment and infrastructure available to workers.
The report estimates that UK workers have 38 per cent fewer tools at their disposal than their counterparts in other advanced economies, rising to 47 per cent in manufacturing sectors. This shortfall, often referred to as the “capital gap”, is seen as a major drag on productivity and competitiveness.
High energy prices are identified as a central factor holding back investment. UK businesses face some of the highest electricity costs in Europe, a situation that has worsened following the recent surge in global gas prices linked to geopolitical tensions in the Middle East.
Pranesh Narayanan, a senior research fellow at the IPPR, said companies are caught in a “double squeeze”.
Advertisement
“Businesses are investing too little while also facing some of the highest electricity costs in Europe, and the two are closely linked,” he said.
Rising energy costs not only increase operating expenses but also reduce the incentive to invest in new facilities or equipment, particularly in energy-intensive industries.
The report calls for adjustments to the government’s planned British Industrial Competitiveness Scheme (BICS), which aims to reduce electricity costs for around 7,000 factories by up to 25 per cent when it launches in 2027.
The IPPR argues that the scheme should be more targeted, focusing on sectors where lower energy costs are most likely to unlock new investment and drive long-term growth.
Advertisement
“With limited fiscal room, support should be directed where it can generate new factories, new equipment and new jobs,” Narayanan said.
The UK’s low investment rate has significant implications for economic performance. Without sufficient capital investment, businesses struggle to improve productivity, which in turn limits wage growth and overall economic expansion.
The issue is particularly acute at a time when the economy is facing additional headwinds from inflation, higher borrowing costs and global uncertainty.
The latest findings reinforce the urgency of addressing the UK’s investment gap, particularly as global competition intensifies and technological change accelerates.
Advertisement
While policy initiatives aimed at reducing energy costs and supporting industry could help, the scale of the challenge suggests that a broader, long-term strategy will be required.
For businesses, the decision to invest will depend on confidence in the economic environment and the cost of operating in the UK. For policymakers, the task is to create conditions that make such investment both viable and attractive.
Without a sustained improvement, the UK risks remaining stuck in a cycle of low investment, weak productivity and subdued growth, a challenge that has persisted for more than a decade.
Jamie Young
Jamie is Senior Reporter at Business Matters, bringing over a decade of experience in UK SME business reporting.
Jamie holds a degree in Business Administration and regularly participates in industry conferences and workshops.
When not reporting on the latest business developments, Jamie is passionate about mentoring up-and-coming journalists and entrepreneurs to inspire the next generation of business leaders.
Shares of Cyclerion Therapeutics Inc. skyrocketed more than 313% Wednesday, surging from around $1.55 at Tuesday’s close to trade near $6.47 midday as the micro-cap biotech announced a transformative all-stock merger with privately held Korsana Biosciences Inc.
FTSE 100 Surges 0.8% Today as Oil Eases and Markets Rebound (Stock Market)
The explosive move came after Cyclerion and Korsana revealed a definitive merger agreement early Wednesday morning, alongside Korsana’s concurrent $380 million oversubscribed private financing. The deal positions the combined company — to be renamed Korsana Biosciences and trade under the ticker “KRSA” — to advance a promising pipeline of next-generation therapies for neurodegenerative diseases, starting with Alzheimer’s.
Volume exploded to more than 213 million shares by midday, dwarfing the company’s typical trading activity and reflecting intense retail and institutional interest in the rare biotech reversal story. Pre-merger Cyclerion shareholders are expected to own roughly 1.5% of the post-deal entity, with Korsana stakeholders (including new financing participants) claiming about 98.5%, subject to net cash adjustments.
“This transaction represents the best path forward for Cyclerion following a comprehensive strategic review,” said Regina Graul, Ph.D., president and CEO of Cyclerion. “Korsana’s promising and innovative pipeline targeting neurodegenerative disorders, beginning with Alzheimer’s disease, provides the potential for significant value creation for Cyclerion’s shareholders.”
Korsana’s lead program, KRSA-028, is a next-generation shuttled monoclonal antibody targeting amyloid beta for Alzheimer’s. It leverages the proprietary Therapeutic Targeting (THETA™) platform, designed to achieve higher brain concentrations while reducing risks such as amyloid-related imaging abnormalities (ARIA) and enabling convenient low-volume subcutaneous dosing.
Advertisement
Deal Details and Strategic Shift
The all-stock merger, approved by both boards, is expected to close in the third quarter of 2026. It remains subject to stockholder approvals, SEC registration effectiveness, Hart-Scott-Rodino antitrust clearance and other customary conditions.
Upon closing, the combined company will operate as Korsana Biosciences Inc., led by Jonathan Violin, Ph.D., as CEO. The board will be chaired by Tomas Kiselak of Fairmount, with directors including representatives from Venrock, Wellington Management and others.
Korsana, which emerged from stealth in February 2026 after raising $175 million in prior rounds (seed from Fairmount and Venrock, plus a $150 million Series A), brings substantial backing from top-tier investors. The new $380 million private placement, led by Fairmount and Venrock Healthcare Capital Partners with participation from General Atlantic, TCGX, Forbion, Wellington, RA Capital, RTW, Vivo, Janus Henderson, Foresite, J.P. Morgan Life Sciences, Sanofi Ventures and others, is expected to extend the combined company’s cash runway into 2029.
Proceeds will fund advancement of KRSA-028, with Phase 1 healthy volunteer data anticipated in mid-2027 and interim proof-of-concept data for amyloid plaque clearance in Alzheimer’s patients by the end of 2027.
Advertisement
Korsana, the seventh company launched from assets developed by Paragon Therapeutics, also maintains a broader pipeline using the THETA™ platform for other undisclosed neurodegenerative conditions with high unmet need.
For Cyclerion, the move marks a sharp pivot. The Cambridge, Massachusetts-based company had been focused on neuropsychiatric therapies, particularly CYC-126 — an anesthetic-based, EEG-guided treatment for treatment-resistant depression (TRD). Recent milestones included positive FDA feedback in February 2026 on its Phase 2 proof-of-concept study plans and a strategic collaboration with Medsteer for closed-loop delivery technology.
Cyclerion had also been monetizing legacy soluble guanylate cyclase (sGC) assets, including out-licenses generating milestone payments. However, with a tiny market capitalization and going-concern warnings in recent filings, the merger with a well-capitalized private player offered a lifeline and potential upside for remaining shareholders despite heavy dilution.
Market Reaction and Investor Sentiment
The 313% surge turned Cyclerion into one of the market’s biggest percentage gainers on April 1, drawing comparisons to other reverse-merger or SPAC-like biotech deals that have delivered quick pops followed by volatility.
Advertisement
Trading forums and social media buzzed with commentary ranging from excitement over the Alzheimer’s angle — amid ongoing interest in amyloid-targeting therapies post-approvals of drugs like Leqembi and Kisunla — to caution about the extreme dilution and execution risks ahead.
Analysts noted that while the deal brings fresh capital and a more advanced pipeline, Cyclerion’s pre-deal shareholders face significant ownership dilution. The stock’s micro-cap status and history of volatility (it has traded as low as around $1 in recent months after earlier surges tied to the TRD pivot) underscore the high-risk nature of the name.
Alzheimer’s Landscape and Korsana’s Differentiation
Korsana enters a competitive but rapidly evolving Alzheimer’s field. Existing anti-amyloid antibodies have shown plaque-clearing benefits but face challenges with safety (ARIA-related brain swelling or microbleeds) and administration (often requiring intravenous infusions).
KRSA-028 aims to stand out through THETA™ technology, which combines transferrin receptor (TfR1) shuttling with Fc engineering for better blood-brain barrier penetration, potentially lower side effects and subcutaneous convenience. Korsana executives believe this could translate to a best-in-class profile.
Advertisement
“Patients deserve better options than what is currently available, and we believe our lead program KRSA-028 can deliver a best-in-class product to treat Alzheimer’s disease,” Violin said. “We are also building a broader pipeline leveraging our proprietary platform to target other devastating neurodegenerative disorders.”
The broader neurodegenerative space remains one of biotech’s highest unmet needs, with aging populations driving demand and investors rewarding companies that can demonstrate differentiated mechanisms or improved safety.
What’s Next for the Combined Company
A conference call was scheduled for Wednesday morning to discuss the transaction. Investors will watch for updates on integration, detailed clinical timelines and any adjustments to ownership percentages based on Cyclerion’s net cash position.
Closing in Q3 2026 would allow the new entity to focus fully on Korsana’s pipeline while maintaining Nasdaq listing continuity under the new ticker.
Advertisement
Risks remain substantial. Clinical development in Alzheimer’s is notoriously challenging, with many programs failing despite promising preclinical data. Regulatory hurdles, competition from larger players and potential integration issues could pressure the stock post-deal.
Cyclerion’s legacy TRD assets and sGC portfolio may be evaluated for further monetization or out-licensing as the company shifts focus.
Broader Context in Biotech M&A
The deal fits a pattern of cash-strapped public biotechs merging with well-funded private innovators to access capital markets and extend runways without traditional IPOs in a selective funding environment. Such reverse mergers can provide liquidity events for private investors while offering public shareholders a reset — albeit often at the cost of heavy dilution.
For retail traders, names like CYCN have occasionally delivered dramatic short-term moves on catalyst-driven days, though sustainability depends on clinical execution.
Advertisement
As of midday Wednesday, the surge showed signs of volatility typical of low-float, high-volume sessions. Longer-term performance will hinge on milestones for KRSA-028 and the strength of the THETA™ platform.
Cyclerion, originally spun out of Ironwood Pharmaceuticals in 2019, has navigated multiple strategic shifts over the years. Wednesday’s announcement could mark its most significant transformation yet.
Investors should monitor official filings, the upcoming registration statement and any post-merger updates from the combined leadership team.
While the April 1 surge provided a dramatic headline, the real test for value creation lies in the clinic and the ability to deliver meaningful advances against neurodegenerative diseases that affect millions worldwide.
You must be logged in to post a comment Login